125 related articles for article (PubMed ID: 33320368)
1. Growth Rate of Ovarian Serous Cystadenomas and Cystadenofibromas.
Frederick RP; Patel AG; Young SW; Dahiya N; Patel MD
J Ultrasound Med; 2021 Oct; 40(10):2123-2130. PubMed ID: 33320368
[TBL] [Abstract][Full Text] [Related]
2. Imaging in gynecological disease (16): clinical and ultrasound characteristics of serous cystadenofibromas in adnexa.
Virgilio BA; De Blasis I; Sladkevicius P; Moro F; Zannoni GF; Arciuolo D; Mascilini F; Ciccarone F; Timmerman D; Kaijser J; Fruscio R; Van Holsbeke C; Franchi D; Epstein E; Leone FPG; Guerriero S; Czekierdowski A; Scambia G; Testa AC; Valentin L
Ultrasound Obstet Gynecol; 2019 Dec; 54(6):823-830. PubMed ID: 30937992
[TBL] [Abstract][Full Text] [Related]
3. Benign ovarian serous tumors: a re-evaluation and proposed reclassification of serous "cystadenomas" and "cystadenofibromas".
Seidman JD; Mehrotra A
Gynecol Oncol; 2005 Feb; 96(2):395-401. PubMed ID: 15661227
[TBL] [Abstract][Full Text] [Related]
4. Cystadenofibromas: Can transvaginal ultrasound appearance reduce some surgical interventions?
Goldstein SR; Timor-Tritsch IE; Monteagudo A; Monda S; Popiolek D
J Clin Ultrasound; 2015; 43(6):393-6. PubMed ID: 25271400
[TBL] [Abstract][Full Text] [Related]
5. Sonographic features of ovarian cystadenofibromas: spectrum of findings.
Alcázar JL; Errasti T; Mínguez JA; Galán MJ; García-Manero M; Ceamanos C
J Ultrasound Med; 2001 Aug; 20(8):915-9. PubMed ID: 11503928
[TBL] [Abstract][Full Text] [Related]
6. Extraovarian cystadenomas: ultrasound and MR findings in 7 cases.
Ghossain MA; Braidy CG; Kanso HN; Farah K; Klein-Tomb L; Trak-Smayra V; Suidan JS; Elhage A; Atallah D; Abboud J
J Comput Assist Tomogr; 2005; 29(1):74-9. PubMed ID: 15665687
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound and Histopathologic Correlation of Ovarian Cystadenofibromas: Diagnostic Value of the "Shadow Sign".
Timor-Tritsch IE; Yoon E; Monteagudo A; Ciaffarano J; Brandon C; Mittal KR; Wallach RC; Boyd LR
J Ultrasound Med; 2019 Nov; 38(11):2973-2978. PubMed ID: 30927305
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional ultrasound and HDlive in tubal serous cystadenofibroma: a case report and literature review.
Grigore M; Popovici R; Furnica C; Pristavu A; Hamod A; Gafitanu D
Med Ultrason; 2017 Nov; 19(4):444-446. PubMed ID: 29197922
[TBL] [Abstract][Full Text] [Related]
9. Microcystic pattern and shadowing are independent predictors of ovarian borderline tumors and cystadenofibromas in ultrasound.
Zheng X; Lyu G; Gan Y; Hu M; Liu X; Chen S; Wu X; Yang W; Ye F; Yan X; Zhang Y
Eur Radiol; 2021 Jan; 31(1):45-54. PubMed ID: 32780208
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
11. Pearls and Potential Pitfalls for Correct Diagnosis of Ovarian Cystadenofibroma in MRI: A Pictorial Essay.
Avesani G; Caliolo G; Gui B; Petta F; Panico C; Manna V; Moro F; Testa AC; Scambia G; Manfredi R
Korean J Radiol; 2021 Nov; 22(11):1809-1821. PubMed ID: 34668348
[TBL] [Abstract][Full Text] [Related]
12. Paraovarian cystadenomas and cystadenofibromas: sonographic characteristics in 14 cases.
Korbin CD; Brown DL; Welch WR
Radiology; 1998 Aug; 208(2):459-62. PubMed ID: 9680576
[TBL] [Abstract][Full Text] [Related]
13. Ovarian Cystadenomas: Growth Rate and Reliability of Imaging Measurements.
Suh-Burgmann E; Nakhaei M; Gupta S; Brook A; Hecht J; Hung YY; Levine D
J Ultrasound Med; 2022 Sep; 41(9):2157-2167. PubMed ID: 34846072
[TBL] [Abstract][Full Text] [Related]
14. Endovaginal sonographic appearance of benign ovarian masses.
Atri M; Nazarnia S; Bret PM; Aldis AE; Kintzen G; Reinhold C
Radiographics; 1994 Jul; 14(4):747-60; discussion 761-2. PubMed ID: 7938766
[TBL] [Abstract][Full Text] [Related]
15. Multiple Intraabdominal and Pelvic Cystadenomas From Ovarian Remnant Syndrome.
Wills E; Grenn EE; Orr WS
Am Surg; 2022 Sep; 88(9):2218-2220. PubMed ID: 35487759
[TBL] [Abstract][Full Text] [Related]
16. Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum.
Hinson SA; Silva EG; Pinto K
Ann Diagn Pathol; 2013 Jun; 17(3):302-4. PubMed ID: 22921726
[TBL] [Abstract][Full Text] [Related]
17. Serous papillary cystadenofibroma of the fallopian tube: A case report and short review of literature.
Khatib Y; Patel RD; Kashikar AS; Chavan K
Indian J Pathol Microbiol; 2015; 58(4):524-7. PubMed ID: 26549083
[TBL] [Abstract][Full Text] [Related]
18. Serous cystadenomas of the pancreas: long-term follow-up measurement of growth rate.
Menard A; Tomlinson G; Cleary S; Wei A; Gallinger S; Haider MA
Can Assoc Radiol J; 2011 Aug; 62(3):190-6. PubMed ID: 20494547
[TBL] [Abstract][Full Text] [Related]
19. Ultrasound Characteristics of Cystadenofibromas: A Retrospective Multicenter Study.
Zheng X; Lyu G; Shen X; Hu M
Ultrasound Q; 2021 Dec; 37(4):349-356. PubMed ID: 34855711
[TBL] [Abstract][Full Text] [Related]
20. Copy number aberrations in benign serous ovarian tumors: a case for reclassification?
Hunter SM; Anglesio MS; Sharma R; Gilks CB; Melnyk N; Chiew YE; deFazio A; ; Longacre TA; Huntsman DG; Gorringe KL; Campbell IG
Clin Cancer Res; 2011 Dec; 17(23):7273-82. PubMed ID: 21976534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
